(Q38211269)

31 August 2017

title

Treatment of lysosomal storage disorders: successes and challenges (English)

1 reference

31 August 2017

Carla E M Hollak

1

1 reference

31 August 2017

Frits A Wijburg

series ordinal

2

1 reference

31 August 2017

publication date

13 May 2014

1 reference

Journal of Inherited Metabolic Disease

31 August 2017

published in

1 reference

31 August 2017

volume

37

1 reference

31 August 2017

issue

4

1 reference

31 August 2017

page(s)

587-598

1 reference

Glycosphingolipids and insulin resistance

31 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9718-3

Elevated globotriaosylsphingosine is a hallmark of Fabry disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9718-3

The clinical outcome of Hurler syndrome after stem cell transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9718-3

Musculoskeletal manifestations of lysosomal storage disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9718-3

Malignancies and monoclonal gammopathy in Gaucher disease; a systematic review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9718-3

The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: lessons learned from infantile Pompe disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9718-3

Algorithm for the early diagnosis and treatment of patients with cross reactive immunologic material-negative classic infantile pompe disease: a step towards improving the efficacy of ERT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9718-3

Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9718-3

Current international perspectives on hematopoietic stem cell transplantation for inherited metabolic disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9718-3

Risk factor analysis of outcomes after unrelated cord blood transplantation in patients with hurler syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9718-3

Spontaneous regression of disease manifestations can occur in type 1 Gaucher disease; results of a retrospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9718-3

Pharmacological chaperones as therapeutics for lysosomal storage diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9718-3

Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9718-3

Haematopoietic cell transplantation (HCT) in combination with enzyme replacement therapy (ERT) in patients with Hurler syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9718-3

Chronic cyclodextrin treatment of murine Niemann-Pick C disease ameliorates neuronal cholesterol and glycosphingolipid storage and disease progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9718-3

Enzyme replacement therapy and/or hematopoietic stem cell transplantation at diagnosis in patients with mucopolysaccharidosis type I: results of a European consensus procedure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9718-3

Cognitive outcome of patients with classic infantile Pompe disease receiving enzyme therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9718-3

Enzyme replacement is associated with better cognitive outcomes after transplant in Hurler syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9718-3

Glucosylceramide transfer from lysosomes--the missing link in molecular pathology of glucosylceramidase deficiency: a hypothesis based on existing data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9718-3

Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9718-3

Transplantation of umbilical-cord blood in babies with infantile Krabbe's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9718-3

Active-site-specific chaperone therapy for Fabry disease. Yin and Yang of enzyme inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9718-3

Improvement in cardiac function in the cardiac variant of Fabry's disease with galactose-infusion therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9718-3

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9718-3

Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9718-3

Treatment of Niemann--pick type C disease by histone deacetylase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9718-3

Miglustat therapy in the French cohort of paediatric patients with Niemann-Pick disease type C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9718-3

Limitations of drug registries to evaluate orphan medicinal products for the treatment of lysosomal storage disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9718-3

Enhanced delivery of α-glucosidase for Pompe disease by ICAM-1-targeted nanocarriers: comparative performance of a strategy for three distinct lysosomal storage disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9718-3

Haematological manifestations and complications of Gaucher disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9718-3

Autopsy case of Gaucher disease type I in a patient on enzyme replacement therapy. Comments on the dynamics of persistent storage process.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9718-3

Gauchers disease--a reappraisal of hematopoietic stem cell transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9718-3

Genistein-mediated inhibition of glycosaminoglycan synthesis, which corrects storage in cells of patients suffering from mucopolysaccharidoses, acts by influencing an epidermal growth factor-dependent pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9718-3

The pharmacological chaperone 1-deoxygalactonojirimycin reduces tissue globotriaosylceramide levels in a mouse model of Fabry disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9718-3

An algorithm to predict phenotypic severity in mucopolysaccharidosis type I in the first month of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9718-3

Hsp70 stabilizes lysosomes and reverts Niemann-Pick disease-associated lysosomal pathology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9718-3

Miglustat therapy in type 1 Gaucher disease: clinical and safety outcomes in a multicenter retrospective cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9718-3

Treatment of hip dysplasia in patients with mucopolysaccharidosis type I after hematopoietic stem cell transplantation: results of an international consensus procedure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9718-3

Histologic findings of femoral heads from patients with Gaucher disease treated with enzyme replacement

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9718-3

Autophagy in lysosomal storage disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9718-3

Reversal of defective lysosomal transport in NPC disease ameliorates liver dysfunction and neurodegeneration in the npc1-/- mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9718-3

Allogeneic hematopoietic stem cell transplantation for treatment of Gaucher disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9718-3

Prevalence of lysosomal storage disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9718-3

Multidisciplinary management of Hunter syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9718-3

Mucopolysaccharidosis I: management and treatment guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9718-3

Iminosugar-based inhibitors of glucosylceramide synthase prolong survival but paradoxically increase brain glucosylceramide levels in Niemann-Pick C mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9718-3

Treatment of lysosomal storage diseases: recent patents and future strategies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9718-3

Functional abnormalities of heparan sulfate in mucopolysaccharidosis-I are associated with defective biologic activity of FGF-2 on human multipotent progenitor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9718-3

Recommendations for the diagnosis and management of Niemann-Pick disease type C: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9718-3

Miglustat for treatment of Niemann-Pick C disease: a randomised controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9718-3

B cell lymphoma and myeloma in murine Gaucher's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9718-3

Miglustat in patients with Niemann-Pick disease Type C (NP-C): a multicenter observational retrospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9718-3

Histone deacetylase inhibitor treatment dramatically reduces cholesterol accumulation in Niemann-Pick type C1 mutant human fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9718-3

The pharmacological chaperone N-butyldeoxynojirimycin enhances enzyme replacement therapy in Pompe disease fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9718-3

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9718-3

The emerging phenotype of long-term survivors with infantile Pompe disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9718-3

Long-term effect of antibodies against infused alpha-galactosidase A in Fabry disease on plasma and urinary (lyso)Gb3 reduction and treatment outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9718-3

Vasculopathy in patients with Fabry disease: current controversies and research directions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9718-3

The incidence of inherited metabolic disorders in the West Midlands, UK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9718-3

Randomized, controlled trial of miglustat in Gaucher's disease type 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9718-3

Respiratory function in late-onset Pompe disease patients receiving long-term enzyme replacement therapy for more than 48 months

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9718-3

Pentosan polysulfate: a novel therapy for the mucopolysaccharidoses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9718-3

Identification of infants at risk for developing Fabry, Pompe, or mucopolysaccharidosis-I from newborn blood spots by tandem mass spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9718-3

Miglustat in late-onset Tay-Sachs disease: a 12-month, randomized, controlled clinical study with 24 months of extended treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9718-3

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9718-3

Mechanism of glycosaminoglycan-mediated bone and joint disease: implications for the mucopolysaccharidoses and other connective tissue diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9718-3

Spinal involvement in mucopolysaccharidosis IVA (Morquio-Brailsford or Morquio A syndrome): presentation, diagnosis and management.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9718-3

Use of a modified alpha-N-acetylgalactosaminidase in the development of enzyme replacement therapy for Fabry disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9718-3

Agalsidase benefits renal histology in young patients with Fabry disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9718-3

Recombinant human alpha-glucosidase from rabbit milk in Pompe patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9718-3

Clinical features and predictors for disease natural progression in adults with Pompe disease: a nationwide prospective observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9718-3

A randomized study of alglucosidase alfa in late-onset Pompe's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9718-3

A systematic review on screening for Fabry disease: prevalence of individuals with genetic variants of unknown significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9718-3

21 January 2018

Niemann-Pick diseases

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9718-3

Gene therapy augments the efficacy of hematopoietic cell transplantation and fully corrects mucopolysaccharidosis type I phenotype in the mouse model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9718-3

Anaesthesia and airway management in mucopolysaccharidosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9718-3

Long-term outcome of enzyme-replacement therapy in advanced Fabry disease: evidence for disease progression towards serious complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9718-3

Fibrosis: a key feature of Fabry disease with potential therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9718-3

Causes of death due to hematological and non-hematological cancers in 57 US patients with type 1 Gaucher Disease who were never treated with enzyme replacement therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9718-3

Enzyme replacement therapy in patients who have mucopolysaccharidosis I and are younger than 5 years: results of a multinational study of recombinant human alpha-L-iduronidase (laronidase).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9718-3

Histone deacetylase inhibitors increase glucocerebrosidase activity in Gaucher disease by modulation of molecular chaperones

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9718-3

Migalastat HCl reduces globotriaosylsphingosine (lyso-Gb3) in Fabry transgenic mice and in the plasma of Fabry patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9718-3

How I treat Gaucher disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9718-3

Synergy between the pharmacological chaperone 1-deoxygalactonojirimycin and the human recombinant alpha-galactosidase A in cultured fibroblasts from patients with Fabry disease

21 January 2018

1 reference

12 December 2020

1 reference

12 December 2020

Musculoskeletal manifestations of Hurler syndrome: long-term follow-up after bone marrow transplantation

1 reference

12 December 2020

Mucopolysaccharidoses and mucolipidoses

1 reference

12 December 2020

Substrate reduction therapy with miglustat in chronic GM2 gangliosidosis type Sandhoff: results of a 3-year follow-up

1 reference

12 December 2020

Neurologic improvement in a type 3 Gaucher disease patient treated with imiglucerase/miglustat combination

1 reference

12 December 2020

Physiotherapy management in late-onset Pompe disease: clinical practice in 88 patients

1 reference

12 December 2020

Persistent bone disease in adult type 1 Gaucher disease despite increasing doses of enzyme replacement therapy

1 reference

12 December 2020

Bone-marrow transplantation in Hurler's syndrome. Effect on skeletal development

1 reference

12 December 2020

Management of neuronopathic Gaucher disease: revised recommendations

1 reference

12 December 2020

Enzyme replacement therapy for lysosomal storage diseases

1 reference

12 December 2020

Hydrophilic iminosugar active-site-specific chaperones increase residual glucocerebrosidase activity in fibroblasts from Gaucher patients

1 reference

12 December 2020

Accelerated transport and maturation of lysosomal α–galactosidase A in Fabry lymphoblasts by an enzyme inhibitor

1 reference

12 December 2020

Ultrastructural analysis of dermal fibroblasts in mucopolysaccharidosis type I: Effects of enzyme replacement therapy and hematopoietic cell transplantation

1 reference

12 December 2020

Agalsidase-beta therapy for advanced Fabry disease: a randomized trial

1 reference

12 December 2020

Genistein in Sanfilippo disease: a randomized controlled crossover trial

1 reference

12 December 2020

ELIGLUSTAT TARTRATE: Glucosylceramide Synthase Inhibitor Treatment of Type 1 Gaucher Disease

1 reference

12 December 2020

Gaucher cells demonstrate a distinct macrophage phenotype and resemble alternatively activated macrophages

1 reference

12 December 2020

10.1007/S10545-014-9718-3

Identifiers

DOI

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/22p6z5u35zcw3ep4gewumdbwye

30 July 2022

mapped directly with Wikidata item

Dimensions Publication ID

1012312383

0 references

Fatcat ID

release_22p6z5u35zcw3ep4gewumdbwye

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/22p6z5u35zcw3ep4gewumdbwye

30 July 2022

mapped directly with Wikidata item

https://api.fatcat.wiki/v0/release/22p6z5u35zcw3ep4gewumdbwye

1 reference

30 July 2022